Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review

BACKGROUND: The selective Janus-activated kinase inhibitor ruxolitinib (rux) is now widely used to treat myelofibrosis and polycythemia vera due to its remarkable effect of reducing splenomegaly and improving constitutional symptoms. With opportunistic infections secondary to rux constantly reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Yizhou, Meng, Li, Hu, Xuemei, Han, Zhiqiang, Hong, Zhenya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532060/
https://www.ncbi.nlm.nih.gov/pubmed/33061478
http://dx.doi.org/10.2147/IDR.S267997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532060/
https://www.ncbi.nlm.nih.gov/pubmed/33061478
http://dx.doi.org/10.2147/IDR.S267997

Ejemplares similares